Table 3.
Therapeutic strategies.
| gNEN | ERa | SR | SSA | CTx | PRRT |
|---|---|---|---|---|---|
| gNEN-1, n | 154 | 13 | 3 | 0 | 1 |
| gNEN-3, n | 9 | 21 | 5 | 8 | 15 |
| gNEN-4, n | 9 | 21 | 4 | 30 | 0 |
| Total, n | 172 | 55 | 12 | 38 | 16 |
gNEN gastric neuroendocrine neoplasia according to Klöppel et al. (2007).
aColumn includes diagnostic interventions without resective intention in gNEN-3 and gNEN-4.
CTx, chemotherapy; EMR, endoscopic mucosa resection; ER, endoscopic resection (including EMR and ESD); ESD, endoscopic submucosa dissection; gNEN, gastric neuroendocrine neoplasia; n, number, (all interventions summarized, cumulative figures); PRRT, peptide receptor radionuclide therapy; SR, surgical resection; SSA, somatostatin analogues.
This work is licensed under a